339094-25-6

Usage

Chemical structure

1-(3,5-dimethoxyphenyl)cyclobutane-1-carbonitrile is a chemical compound with a cyclobutane ring and a carbonitrile group attached to one of the carbon atoms, as well as a 3,5-dimethoxyphenyl group attached to a different carbon atom.

Potential applications

1-(3,5-dimethoxyphenyl)cyclobutane-1-carbonitrile is of interest due to its potential applications in pharmaceuticals and other industries.

Biological activity

It may possess biological activity, which could make it useful in the development of new drugs or therapies.

Building block

1-(3,5-dimethoxyphenyl)cyclobutane-1-carbonitrile could be used as a building block in the synthesis of other organic compounds.

Further research

The specific properties and potential uses of 1-(3,5-dimethoxyphenyl)cyclobutane-1-carbonitrile may warrant further research and investigation to fully understand its capabilities and applications.

Upstream product

• 13388-75-5 3,5-dimethoxyphenylacetonitrile 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 941583-85-3 5-[1-[(1Z)-1-hexenyl]cyclobutyl]resorcinol 
• 951039-78-4 5-(1-heptylcyclobutyl)resorcinol 
• 941583-84-2 5-(1-hexylcyclobutyl)resorcinol 
• 951039-73-9 3,5-dimethoxy-1-(1-heptylcyclobutyl)benzene 
• 951039-70-6 3,5-dimethoxy-1-(1-hexylcyclobutyl)benzene 
• 951039-67-1 3,5-dimethoxy-1-[1-[(1Z)-1-heptenyl]cyclobutyl]benzene 
• 951039-64-8 3,5-dimethoxy-1-[1-[(1Z)-1-hexenyl]cyclobutyl]benzene 
• 339094-29-0 1-(3,5-dimethoxyphenyl)cyclobutanecarboxaldehyde 

Relevant academic research and scientific papers

Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists

In earlier work, we explored the SAR for the C3 side chain pharmacophore in the hexahydrocannabinol template represented by the drug nabilone, which resulted in the development of AM2389. In an effort for further optimization, we have merged features of n

Synthesis method of arylcyclobutane compound

The present invention discloses a method for synthesizing an arylcyclobutane compound to 1eq phenylacetonitrile and 1.1eq 1-bromo-3-chloropropane as raw material, N,N- dimethylacetamide as a solvent, plus 2.5eq sodium hydride, under the protection of iner

Controlled-deactivation cannabinergic ligands

We report an approach for obtaining novel cannabinoid analogues with controllable deactivation and improved druggability. Our design involves the incorporation of a metabolically labile ester group at the 2′-position on a series of (-)-Δ8-THC a

C1′-cycloalkyl side chain pharmacophore in tetrahydrocannabinols

In earlier work we have provided evidence for the presence of a subsite within the CB1 and CB2 cannabinoid receptor binding domains of classical cannabinoids. This putative subsite corresponds to substituents on the C1-position of the C3-alkyl side chain, a key pharmacophoric feature in this class of compounds. We have now refined this work through the synthesis of additional C1′-cycloalkyl compounds using newly developed approaches. Our findings indicate that the C1′-cyclopropyl and C1′-cyclopentyl groups are optimal pharmacophores for both receptors while the C1′-cyclobutyl group interacts optimally with CB1 but not with CB2. The C1′-cyclohexyl analogs have reduced affinities for both CB1 and CB2. However, these affinities are significantly improved with the introduction of a C2′-C3′ cis double bond that modifies the available conformational space within the side chain and allows for a better accommodation of a six-membered ring within the side chain subsite. Our SAR results are highlighted by molecular modeling of key analogs.

A New Ring-Forming Methodology for the Synthesis of Conformationally Constrained Bioactive Molecules

A new, general, one pot method for introducing carboxylic rings alpha to a nitrile moiety is described. Treatment of readily available arylacetonitriles with potassium bis(trimethylsilyl)amide and subsequent alkylation with α,ω-dibromo or dichloroalkanes